Holen Sie sich die Stockscreener-App
11.64
2.02%
0.23
Handel nachbörslich:
11.64
Schlusskurs vom Vortag:
$11.41
Offen:
$11.54
24-Stunden-Volumen:
183.80K
Relative Volume:
0.24
Marktkapitalisierung:
$634.80M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+14.12%
1M Leistung:
+13.78%
6M Leistung:
-13.65%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.20
$11.69
1-Wochen-Bereich:
$9.57
$11.69
52-Wochen-Spanne:
$7.80
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Firmenname
Bicara Therapeutics Inc
Sektor
Branche
Telefon
617-468-4219
Adresse
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Vergleichen Sie BCAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
11.64 | 622.56M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-23 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2025-04-17 | Eingeleitet | Wells Fargo | Underweight |
| 2025-02-06 | Eingeleitet | Wedbush | Outperform |
| 2024-12-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
| 2024-10-08 | Eingeleitet | TD Cowen | Buy |
Alle ansehen
Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten
Promising Clinical Developments and Financial Stability Drive Buy Rating for Bicara Therapeutics - TipRanks
Bicara Therapeutics Inc. Shares Could Surge 187.73% as Analysts Expect - AInvest
Does Bicara Therapeutics Inc. (BCAX) Have the Potential to Rally 187.73% as Wall Street Analysts Expect? - Yahoo Finance
Bicara Therapeutics Reports Q2 2025 Results and Progress - TipRanks
Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Bicara Therapeutics reports Q2 EPS (50c), consensus (54c) - MSN
Bicara Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Bicara Therapeutics and the Breakthrough Potential of Ficerafusp Alfa in Solid Tumors: A High-Conviction Biotech Investment in the Oncology Innovation Space - AInvest
Can Bicara Therapeutics Inc. sustain earnings growthStable Return Investment Forecast - thegnnews.com
Bicara Therapeutics BCAX 2025Q2 Earnings Preview Downside Ahead on Revenue Concerns - AInvest
Price Channel Expanding on Bicara Therapeutics Inc.’s ChartEarly Entry Picks Before News Breakout Reviewed - beatles.ru
Is Bicara Therapeutics Inc. stock overvalued or undervaluedStrong return on investment - Jammu Links News
How volatile is Bicara Therapeutics Inc. stock compared to the marketMaximize returns with disciplined trading - Jammu Links News
What analysts say about Bicara Therapeutics Inc. stockUnprecedented profits - Jammu Links News
What is Bicara Therapeutics Inc. company’s growth strategyMaximize gains with expert analysis - Jammu Links News
What are the latest earnings results for Bicara Therapeutics Inc.Exceptional stock performance - Jammu Links News
How does Bicara Therapeutics Inc. compare to its industry peersPhenomenal capital appreciation - Jammu Links News
Does Bicara Therapeutics Inc. stock perform well during market downturnsTake advantage of unprecedented market momentum - Jammu Links News
Is Bicara Therapeutics Inc. the Top Chart Pick This WeekEntry Points For Growing Stocks Identified by Models - beatles.ru
Is it the right time to buy Bicara Therapeutics Inc. stockBreakout Stocks Tips That Work - jammulinksnews.com
What institutional investors are buying Bicara Therapeutics Inc. stockLow Risk Recommendation That Work - Jammu Links News
Published on: 2025-07-31 05:01:42 - beatles.ru
Will Bicara Therapeutics Inc. Benefit From Broader Market BounceROI Boosting Trade Opportunity Calendar Published - metal.it
Bicara Therapeutics Inc. Inches Above Key Support — Safe to HoldWealth Building Stock Market Ideas Based on Momentum - metal.it
RSI Crosses Above 30 for Bicara Therapeutics Inc. — Reversal in SightGrowth Based Investment Plan Guidance Highlighted - metal.it
Bicara Therapeutics Inc. Shows Risk Reward Favoring UpsideEntry Alert Based on Volume Spikes Detected - metal.it
Will Bicara Therapeutics Inc. Recover After Recent DeclineConservative Entry for High Return Setup Backed - beatles.ru
When is Bicara Therapeutics Inc. stock expected to show significant growthSmart Portfolio Strategy For Beginners - Jammu Links News
How Bicara Therapeutics Inc. stock performs during market volatilityValue Investing Picks With Stability Outlined - metal.it
Bicara Therapeutics Inc. Stock Approaches Key Moving AverageROI Driven Equity Selection With Safety Emphasized - metal.it
Real time breakdown of Bicara Therapeutics Inc. stock performanceDaily Stock Forecast Powered by AI Tools - Newser
Why is Bicara Therapeutics Inc. stock attracting strong analyst attentionGain access to exclusive stock analysis - Jammu Links News
Bicara Therapeutics Inc. Stock Performance After Earnings: Historical InsightsDefensive Stock Picks with Upside - Newser
Is Bicara Therapeutics Inc. a good long term investmentExceptional stock performance - PrintWeekIndia
What drives Bicara Therapeutics Inc. stock priceSky-high return potential - PrintWeekIndia
What analysts say about Bicara Therapeutics Inc. stock outlookSuperior investment outcomes - Jammu Links News
Is Bicara Therapeutics Inc. stock a good hedge against inflationExtraordinary profit generation - jammulinksnews.com
Finanzdaten der Bicara Therapeutics Inc-Aktie (BCAX)
Es liegen keine Finanzdaten für Bicara Therapeutics Inc (BCAX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):